Immunomedics, Inc., a biopharmaceutical company focused on third world nation monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial operation in an initial set of clients treated with a conjugation of the vaccine labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the red white and blue confederation for Cancer Research.

More: - Continued here